Century Therapeutics, Inc. (IPSC) Reports In-Line Q2 EPS

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• GuideAI Health hires firms for marketing and investor outreach
• Occidental Petroleum releases Q2 2026 earnings considerations